Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thyroid Neoplasms | 79 | 2024 | 2355 | 10.570 |
Why?
|
Quinolines | 15 | 2024 | 769 | 4.570 |
Why?
|
Phenylurea Compounds | 17 | 2024 | 533 | 4.530 |
Why?
|
Proto-Oncogene Proteins c-ret | 18 | 2024 | 228 | 4.320 |
Why?
|
Iodine Radioisotopes | 26 | 2024 | 1030 | 3.780 |
Why?
|
Carcinoma, Neuroendocrine | 17 | 2024 | 343 | 3.660 |
Why?
|
Head and Neck Neoplasms | 45 | 2025 | 2930 | 2.700 |
Why?
|
Protein Kinase Inhibitors | 32 | 2024 | 5690 | 2.490 |
Why?
|
Pyrazoles | 15 | 2024 | 2030 | 2.180 |
Why?
|
Carcinoma, Squamous Cell | 39 | 2019 | 4050 | 2.060 |
Why?
|
Pyridines | 20 | 2024 | 2888 | 1.800 |
Why?
|
Radiation Tolerance | 9 | 2021 | 476 | 1.710 |
Why?
|
Oncogene Proteins, Fusion | 6 | 2024 | 1608 | 1.630 |
Why?
|
Antineoplastic Agents | 42 | 2024 | 13644 | 1.570 |
Why?
|
Proto-Oncogene Proteins B-raf | 12 | 2022 | 2056 | 1.330 |
Why?
|
Carcinoma | 9 | 2020 | 2325 | 1.210 |
Why?
|
Anilides | 9 | 2024 | 413 | 1.140 |
Why?
|
Oropharyngeal Neoplasms | 5 | 2022 | 492 | 1.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 28 | 2024 | 11876 | 1.070 |
Why?
|
Carcinoma, Papillary | 9 | 2022 | 791 | 1.050 |
Why?
|
Receptor, trkA | 6 | 2024 | 159 | 0.910 |
Why?
|
Indazoles | 2 | 2024 | 306 | 0.910 |
Why?
|
Adenoma, Oxyphilic | 4 | 2024 | 151 | 0.900 |
Why?
|
Lung Neoplasms | 14 | 2024 | 13489 | 0.900 |
Why?
|
Papillomavirus Infections | 8 | 2022 | 1639 | 0.870 |
Why?
|
Carcinoma, Medullary | 6 | 2023 | 115 | 0.860 |
Why?
|
Neoplasms, Squamous Cell | 4 | 2012 | 95 | 0.850 |
Why?
|
Molecular Targeted Therapy | 8 | 2021 | 2823 | 0.840 |
Why?
|
Adenocarcinoma, Follicular | 4 | 2024 | 323 | 0.780 |
Why?
|
Adenocarcinoma | 7 | 2024 | 6359 | 0.740 |
Why?
|
Quinazolines | 8 | 2024 | 1367 | 0.710 |
Why?
|
Mutation | 26 | 2024 | 30214 | 0.660 |
Why?
|
Papillomaviridae | 5 | 2022 | 1139 | 0.660 |
Why?
|
Neoplasm Metastasis | 18 | 2025 | 4892 | 0.640 |
Why?
|
Lymphocyte Count | 1 | 2021 | 794 | 0.630 |
Why?
|
Mouth Neoplasms | 3 | 2017 | 597 | 0.590 |
Why?
|
Thyroid Nodule | 4 | 2021 | 765 | 0.570 |
Why?
|
Pyrimidines | 5 | 2024 | 3043 | 0.570 |
Why?
|
Leukocyte Count | 1 | 2021 | 1606 | 0.550 |
Why?
|
Carcinoma, Adenoid Cystic | 5 | 2024 | 262 | 0.530 |
Why?
|
Thyroid Gland | 5 | 2023 | 1170 | 0.530 |
Why?
|
Humans | 170 | 2025 | 766812 | 0.510 |
Why?
|
Neoplasm Recurrence, Local | 13 | 2025 | 9407 | 0.490 |
Why?
|
Sulfonamides | 4 | 2016 | 1982 | 0.480 |
Why?
|
Gene Fusion | 4 | 2023 | 356 | 0.470 |
Why?
|
Indoles | 6 | 2016 | 1834 | 0.470 |
Why?
|
Respiratory Rate | 1 | 2016 | 179 | 0.470 |
Why?
|
Cell Differentiation | 6 | 2024 | 11657 | 0.460 |
Why?
|
Niacinamide | 6 | 2015 | 419 | 0.460 |
Why?
|
Thyroidectomy | 10 | 2024 | 912 | 0.450 |
Why?
|
Combined Modality Therapy | 21 | 2021 | 8540 | 0.450 |
Why?
|
Carboplatin | 10 | 2024 | 790 | 0.410 |
Why?
|
Aged | 69 | 2025 | 171344 | 0.400 |
Why?
|
Genes, Neoplasm | 1 | 2014 | 369 | 0.390 |
Why?
|
Treatment Outcome | 38 | 2025 | 65286 | 0.380 |
Why?
|
Infratentorial Neoplasms | 1 | 2012 | 99 | 0.380 |
Why?
|
Chemoprevention | 1 | 2014 | 327 | 0.380 |
Why?
|
Middle Aged | 77 | 2025 | 223267 | 0.370 |
Why?
|
Acoustic Stimulation | 1 | 2016 | 1253 | 0.370 |
Why?
|
Male | 90 | 2025 | 364154 | 0.370 |
Why?
|
Pyrroles | 3 | 2014 | 1121 | 0.360 |
Why?
|
Clinical Trials as Topic | 7 | 2019 | 8045 | 0.360 |
Why?
|
Salivary Gland Neoplasms | 3 | 2021 | 306 | 0.350 |
Why?
|
Gene Rearrangement | 3 | 2021 | 1141 | 0.340 |
Why?
|
Female | 91 | 2025 | 396532 | 0.340 |
Why?
|
Paranasal Sinuses | 1 | 2012 | 267 | 0.340 |
Why?
|
Double-Blind Method | 13 | 2024 | 12430 | 0.330 |
Why?
|
Taxoids | 9 | 2016 | 665 | 0.320 |
Why?
|
Carcinoid Tumor | 2 | 2014 | 225 | 0.310 |
Why?
|
Neutrophils | 1 | 2021 | 3782 | 0.300 |
Why?
|
Aged, 80 and over | 30 | 2025 | 59548 | 0.300 |
Why?
|
Monitoring, Physiologic | 1 | 2016 | 1794 | 0.300 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2024 | 5330 | 0.280 |
Why?
|
Adult | 57 | 2024 | 223305 | 0.270 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 4 | 2017 | 661 | 0.270 |
Why?
|
Benzamides | 2 | 2024 | 1375 | 0.270 |
Why?
|
Carcinoma, Ductal | 2 | 2020 | 96 | 0.270 |
Why?
|
Kaplan-Meier Estimate | 10 | 2020 | 6514 | 0.270 |
Why?
|
Imidazoles | 3 | 2020 | 1168 | 0.260 |
Why?
|
Radiotherapy, Computer-Assisted | 1 | 2006 | 90 | 0.260 |
Why?
|
Infant, Premature | 1 | 2016 | 2120 | 0.260 |
Why?
|
Piperidines | 5 | 2024 | 1663 | 0.260 |
Why?
|
Proto-Oncogene Proteins c-met | 3 | 2020 | 562 | 0.250 |
Why?
|
Radiotherapy, Intensity-Modulated | 5 | 2015 | 798 | 0.250 |
Why?
|
Tumor Burden | 2 | 2022 | 1902 | 0.250 |
Why?
|
Neoplasms | 10 | 2023 | 22350 | 0.250 |
Why?
|
Neoadjuvant Therapy | 3 | 2024 | 2902 | 0.240 |
Why?
|
Medical Oncology | 6 | 2022 | 2340 | 0.230 |
Why?
|
Herpesvirus 4, Human | 3 | 2024 | 1080 | 0.230 |
Why?
|
Heart Rate | 1 | 2016 | 4207 | 0.230 |
Why?
|
Disease-Free Survival | 15 | 2018 | 6853 | 0.230 |
Why?
|
Nasopharyngeal Neoplasms | 3 | 2024 | 289 | 0.230 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2024 | 1802 | 0.230 |
Why?
|
Diarrhea | 3 | 2022 | 1317 | 0.220 |
Why?
|
Laryngeal Neoplasms | 3 | 2018 | 514 | 0.220 |
Why?
|
Disease Management | 3 | 2024 | 2533 | 0.200 |
Why?
|
Aphasia | 1 | 2024 | 193 | 0.200 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2019 | 1105 | 0.200 |
Why?
|
Chylous Ascites | 1 | 2022 | 21 | 0.200 |
Why?
|
Recurrent Laryngeal Nerve | 1 | 2024 | 145 | 0.200 |
Why?
|
Neoplasm Proteins | 2 | 2014 | 3600 | 0.200 |
Why?
|
Survival Rate | 11 | 2021 | 12826 | 0.190 |
Why?
|
Cisplatin | 9 | 2016 | 1656 | 0.190 |
Why?
|
Phosphotransferases | 2 | 2021 | 302 | 0.190 |
Why?
|
Maximum Tolerated Dose | 5 | 2020 | 896 | 0.190 |
Why?
|
Chylothorax | 1 | 2022 | 83 | 0.190 |
Why?
|
Hypertension | 2 | 2020 | 8616 | 0.190 |
Why?
|
Precancerous Conditions | 1 | 2008 | 980 | 0.190 |
Why?
|
Neoplasm Staging | 17 | 2024 | 11218 | 0.190 |
Why?
|
Radiotherapy, Adjuvant | 7 | 2015 | 1788 | 0.190 |
Why?
|
Oncogene Fusion | 1 | 2021 | 84 | 0.180 |
Why?
|
Salvage Therapy | 3 | 2017 | 1274 | 0.180 |
Why?
|
Nuclear Receptor Coactivators | 1 | 2021 | 62 | 0.180 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2023 | 2426 | 0.180 |
Why?
|
Papillomavirus Vaccines | 2 | 2019 | 497 | 0.180 |
Why?
|
Calcitonin | 4 | 2019 | 327 | 0.180 |
Why?
|
Thyroglobulin | 4 | 2014 | 111 | 0.180 |
Why?
|
Vocal Cord Paralysis | 1 | 2024 | 275 | 0.180 |
Why?
|
Molecular Diagnostic Techniques | 3 | 2020 | 614 | 0.170 |
Why?
|
Disease Progression | 12 | 2023 | 13642 | 0.170 |
Why?
|
Iodine | 1 | 2022 | 285 | 0.170 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 4 | 2022 | 5389 | 0.170 |
Why?
|
Deoxycytidine | 1 | 2024 | 886 | 0.170 |
Why?
|
Xeroderma Pigmentosum | 1 | 2019 | 31 | 0.170 |
Why?
|
Liver Neoplasms | 3 | 2023 | 4356 | 0.170 |
Why?
|
Transaminases | 1 | 2020 | 198 | 0.170 |
Why?
|
Retrospective Studies | 22 | 2025 | 81657 | 0.170 |
Why?
|
Radiopharmaceuticals | 4 | 2023 | 2703 | 0.160 |
Why?
|
Papillomavirus E7 Proteins | 1 | 2019 | 109 | 0.160 |
Why?
|
Intention to Treat Analysis | 1 | 2020 | 418 | 0.160 |
Why?
|
Antibodies, Monoclonal | 5 | 2016 | 9244 | 0.160 |
Why?
|
Alphapapillomavirus | 1 | 2022 | 219 | 0.160 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2021 | 3667 | 0.160 |
Why?
|
Proto-Oncogene Proteins | 3 | 2023 | 4523 | 0.160 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2020 | 329 | 0.150 |
Why?
|
Oximes | 2 | 2022 | 305 | 0.150 |
Why?
|
Tretinoin | 1 | 2021 | 524 | 0.150 |
Why?
|
Triazines | 1 | 2020 | 311 | 0.150 |
Why?
|
Young Adult | 14 | 2024 | 59939 | 0.150 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2022 | 878 | 0.150 |
Why?
|
Paclitaxel | 7 | 2016 | 1728 | 0.150 |
Why?
|
Survival Analysis | 6 | 2021 | 10101 | 0.150 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2018 | 3552 | 0.140 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2020 | 638 | 0.140 |
Why?
|
Bone Neoplasms | 2 | 2022 | 2561 | 0.140 |
Why?
|
DNA, Mitochondrial | 2 | 2023 | 872 | 0.140 |
Why?
|
Multicenter Studies as Topic | 1 | 2022 | 1733 | 0.140 |
Why?
|
Tracheotomy | 1 | 2018 | 174 | 0.140 |
Why?
|
Radiation Oncology | 1 | 2023 | 572 | 0.140 |
Why?
|
Biopsy, Fine-Needle | 3 | 2020 | 1131 | 0.130 |
Why?
|
Activin Receptors, Type II | 1 | 2016 | 122 | 0.130 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2023 | 1621 | 0.120 |
Why?
|
Estrogen Receptor alpha | 1 | 2019 | 581 | 0.120 |
Why?
|
Prognosis | 14 | 2023 | 29959 | 0.120 |
Why?
|
ras Proteins | 2 | 2020 | 1055 | 0.120 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2019 | 4652 | 0.120 |
Why?
|
Anemia | 1 | 2024 | 1514 | 0.120 |
Why?
|
Cranial Irradiation | 1 | 2017 | 392 | 0.120 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2023 | 2028 | 0.120 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 2016 | 287 | 0.120 |
Why?
|
Oncogenes | 1 | 2020 | 1232 | 0.110 |
Why?
|
Blood Pressure Determination | 1 | 2018 | 646 | 0.110 |
Why?
|
Neoplasms, Experimental | 1 | 2019 | 1228 | 0.110 |
Why?
|
Human papillomavirus 16 | 1 | 2016 | 268 | 0.110 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2021 | 934 | 0.110 |
Why?
|
Proteinuria | 1 | 2017 | 613 | 0.110 |
Why?
|
Trypsin Inhibitor, Bowman-Birk Soybean | 1 | 2013 | 3 | 0.110 |
Why?
|
Placebos | 1 | 2018 | 1659 | 0.110 |
Why?
|
Time Factors | 8 | 2021 | 40149 | 0.110 |
Why?
|
Trypsin Inhibitors | 1 | 2013 | 32 | 0.110 |
Why?
|
Recovery of Function | 1 | 2024 | 2978 | 0.110 |
Why?
|
Protein Kinases | 1 | 2020 | 1610 | 0.110 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2013 | 10745 | 0.110 |
Why?
|
Leukoplakia, Oral | 1 | 2013 | 79 | 0.100 |
Why?
|
Whole Body Imaging | 1 | 2014 | 283 | 0.100 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2014 | 904 | 0.100 |
Why?
|
Immunotherapy | 3 | 2025 | 4747 | 0.100 |
Why?
|
Exanthema | 1 | 2017 | 502 | 0.100 |
Why?
|
Cranial Nerve Diseases | 1 | 2012 | 111 | 0.100 |
Why?
|
Immunotherapy, Adoptive | 2 | 2024 | 1503 | 0.100 |
Why?
|
Ischemic Attack, Transient | 1 | 2017 | 874 | 0.100 |
Why?
|
Hydroxamic Acids | 1 | 2015 | 483 | 0.100 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1776 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2021 | 2882 | 0.090 |
Why?
|
Skull Neoplasms | 1 | 2012 | 173 | 0.090 |
Why?
|
Gallbladder | 1 | 2013 | 308 | 0.090 |
Why?
|
Fluorouracil | 7 | 2016 | 1652 | 0.090 |
Why?
|
Deglutition Disorders | 2 | 2008 | 640 | 0.090 |
Why?
|
Lymphatic Diseases | 1 | 2013 | 318 | 0.090 |
Why?
|
Capsid Proteins | 1 | 2014 | 468 | 0.090 |
Why?
|
Sarcoma | 1 | 2022 | 1802 | 0.090 |
Why?
|
Paralysis | 1 | 2012 | 250 | 0.090 |
Why?
|
Diagnosis, Differential | 3 | 2024 | 12985 | 0.090 |
Why?
|
Genotype | 4 | 2014 | 13036 | 0.090 |
Why?
|
Drug Administration Schedule | 4 | 2020 | 4853 | 0.090 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2023 | 2329 | 0.090 |
Why?
|
Epstein-Barr Virus Infections | 2 | 2024 | 617 | 0.090 |
Why?
|
Oncogene Proteins | 1 | 2014 | 715 | 0.090 |
Why?
|
Hedgehog Proteins | 1 | 2014 | 771 | 0.090 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2016 | 646 | 0.080 |
Why?
|
Quality of Life | 6 | 2024 | 13476 | 0.080 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2010 | 102 | 0.080 |
Why?
|
Fatigue | 1 | 2017 | 1555 | 0.080 |
Why?
|
Opportunistic Infections | 1 | 2012 | 376 | 0.080 |
Why?
|
Thyrotropin | 1 | 2013 | 834 | 0.080 |
Why?
|
Gene Expression Profiling | 3 | 2021 | 9528 | 0.080 |
Why?
|
Gene Expression | 2 | 2019 | 7585 | 0.080 |
Why?
|
Hypopharyngeal Neoplasms | 1 | 2009 | 52 | 0.080 |
Why?
|
Amifostine | 2 | 2009 | 39 | 0.080 |
Why?
|
Treatment Failure | 1 | 2015 | 2659 | 0.080 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2019 | 3114 | 0.080 |
Why?
|
Oncogene Protein v-akt | 1 | 2008 | 130 | 0.080 |
Why?
|
Recombinant Fusion Proteins | 2 | 2016 | 3738 | 0.080 |
Why?
|
Tumor Microenvironment | 2 | 2019 | 3942 | 0.080 |
Why?
|
Retreatment | 3 | 2017 | 598 | 0.080 |
Why?
|
Antihypertensive Agents | 1 | 2018 | 2030 | 0.080 |
Why?
|
Esophageal Stenosis | 2 | 2010 | 196 | 0.080 |
Why?
|
Angiogenesis Inhibitors | 3 | 2016 | 2057 | 0.070 |
Why?
|
Neck | 1 | 2013 | 736 | 0.070 |
Why?
|
Epstein-Barr Virus Nuclear Antigens | 1 | 2009 | 158 | 0.070 |
Why?
|
Neck Dissection | 2 | 2006 | 201 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2012 | 1838 | 0.070 |
Why?
|
Biological Therapy | 1 | 2008 | 140 | 0.070 |
Why?
|
Carbazoles | 2 | 2019 | 230 | 0.070 |
Why?
|
Tonsillar Neoplasms | 1 | 2007 | 49 | 0.070 |
Why?
|
Lymphatic Metastasis | 4 | 2024 | 2901 | 0.070 |
Why?
|
Gestational Age | 1 | 2016 | 3617 | 0.070 |
Why?
|
Relative Biological Effectiveness | 1 | 2008 | 313 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2022 | 10384 | 0.070 |
Why?
|
Otorhinolaryngologic Neoplasms | 1 | 2006 | 26 | 0.070 |
Why?
|
Ki-67 Antigen | 1 | 2008 | 630 | 0.070 |
Why?
|
Adolescent | 6 | 2022 | 88902 | 0.070 |
Why?
|
Technology, Pharmaceutical | 1 | 2006 | 83 | 0.070 |
Why?
|
Cyclooxygenase 2 | 1 | 2008 | 597 | 0.060 |
Why?
|
Dinoprostone | 1 | 2008 | 597 | 0.060 |
Why?
|
Brain | 1 | 2012 | 27158 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2014 | 2456 | 0.060 |
Why?
|
DNA Damage | 1 | 2015 | 2469 | 0.060 |
Why?
|
Meta-Analysis as Topic | 2 | 2008 | 1365 | 0.060 |
Why?
|
Radiotherapy, Conformal | 1 | 2008 | 545 | 0.060 |
Why?
|
Hypopharynx | 1 | 2004 | 53 | 0.060 |
Why?
|
Incidence | 3 | 2019 | 21527 | 0.060 |
Why?
|
Xerostomia | 3 | 2010 | 94 | 0.060 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2024 | 193 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 3 | 2024 | 20710 | 0.060 |
Why?
|
Lipid Peroxides | 1 | 2023 | 74 | 0.050 |
Why?
|
Melanoma | 1 | 2022 | 5702 | 0.050 |
Why?
|
Radiation-Protective Agents | 1 | 2003 | 87 | 0.050 |
Why?
|
Larynx | 1 | 2008 | 492 | 0.050 |
Why?
|
Diagnostic Imaging | 1 | 2017 | 3530 | 0.050 |
Why?
|
Oxyphil Cells | 1 | 2023 | 56 | 0.050 |
Why?
|
Tropomyosin | 1 | 2023 | 105 | 0.050 |
Why?
|
Oligonucleotides | 3 | 2013 | 561 | 0.050 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2024 | 258 | 0.050 |
Why?
|
Radiation Injuries | 2 | 2008 | 1195 | 0.050 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2024 | 212 | 0.050 |
Why?
|
Fermentation | 1 | 2023 | 143 | 0.050 |
Why?
|
Gastroscopy | 1 | 2004 | 213 | 0.050 |
Why?
|
Administration, Oral | 2 | 2014 | 4019 | 0.050 |
Why?
|
Pain | 2 | 2022 | 5098 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2017 | 5306 | 0.050 |
Why?
|
Neoplasms, Second Primary | 1 | 2010 | 1062 | 0.050 |
Why?
|
Macrophages | 1 | 2017 | 5784 | 0.050 |
Why?
|
Brain Neoplasms | 2 | 2018 | 9101 | 0.050 |
Why?
|
Pilot Projects | 3 | 2017 | 8728 | 0.050 |
Why?
|
Immunoenzyme Techniques | 2 | 2016 | 1697 | 0.050 |
Why?
|
Cell Line, Tumor | 4 | 2020 | 17089 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 1405 | 0.050 |
Why?
|
Radiotherapy Dosage | 4 | 2010 | 2916 | 0.050 |
Why?
|
Interleukin-8 | 1 | 2005 | 703 | 0.050 |
Why?
|
Immunohistochemistry | 3 | 2021 | 11062 | 0.050 |
Why?
|
Lymph Nodes | 1 | 2013 | 3468 | 0.050 |
Why?
|
Biomedical Research | 1 | 2017 | 3459 | 0.050 |
Why?
|
Thyroid Function Tests | 1 | 2022 | 289 | 0.050 |
Why?
|
Remission Induction | 2 | 2006 | 2413 | 0.050 |
Why?
|
Massachusetts | 1 | 2014 | 8890 | 0.050 |
Why?
|
Algorithms | 1 | 2021 | 14073 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2020 | 6965 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2021 | 313 | 0.040 |
Why?
|
Signal Transduction | 4 | 2019 | 23618 | 0.040 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 1994 | 388 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2013 | 5536 | 0.040 |
Why?
|
Databases, Factual | 3 | 2021 | 8065 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2019 | 5860 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2018 | 3605 | 0.040 |
Why?
|
Pyrimidinones | 1 | 2022 | 385 | 0.040 |
Why?
|
Ultrasonography | 1 | 2013 | 5990 | 0.040 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2021 | 348 | 0.040 |
Why?
|
Patient Compliance | 1 | 2009 | 2694 | 0.040 |
Why?
|
Poly I-C | 1 | 2019 | 110 | 0.040 |
Why?
|
Mental Disorders | 1 | 2019 | 6869 | 0.040 |
Why?
|
Laryngoscopy | 1 | 2004 | 714 | 0.040 |
Why?
|
Phenotype | 2 | 2020 | 16722 | 0.040 |
Why?
|
Mass Screening | 1 | 2014 | 5454 | 0.040 |
Why?
|
Haploidy | 1 | 2018 | 128 | 0.040 |
Why?
|
Risk Assessment | 4 | 2018 | 24299 | 0.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 2 | 2016 | 617 | 0.040 |
Why?
|
Injections, Intramuscular | 1 | 2019 | 551 | 0.040 |
Why?
|
Cohort Studies | 4 | 2020 | 41706 | 0.040 |
Why?
|
Follow-Up Studies | 6 | 2017 | 39312 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 859 | 0.040 |
Why?
|
Annual Reports as Topic | 1 | 2017 | 36 | 0.040 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 12536 | 0.030 |
Why?
|
Therapeutics | 1 | 2017 | 113 | 0.030 |
Why?
|
Clonal Anergy | 1 | 2017 | 169 | 0.030 |
Why?
|
International Agencies | 1 | 2017 | 244 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2024 | 21162 | 0.030 |
Why?
|
Cytodiagnosis | 1 | 2020 | 450 | 0.030 |
Why?
|
Pyridones | 1 | 2022 | 818 | 0.030 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2017 | 126 | 0.030 |
Why?
|
Platinum Compounds | 1 | 2017 | 94 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2022 | 862 | 0.030 |
Why?
|
Prospective Studies | 5 | 2024 | 54872 | 0.030 |
Why?
|
Tyrosine | 1 | 2020 | 1425 | 0.030 |
Why?
|
United States | 6 | 2022 | 72945 | 0.030 |
Why?
|
Propensity Score | 1 | 2024 | 1972 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2016 | 26387 | 0.030 |
Why?
|
Societies, Medical | 2 | 2018 | 3957 | 0.030 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2019 | 1352 | 0.030 |
Why?
|
Breast | 1 | 2024 | 1972 | 0.030 |
Why?
|
Animals | 9 | 2020 | 168939 | 0.030 |
Why?
|
Amygdala | 1 | 2023 | 1375 | 0.030 |
Why?
|
Drug Approval | 1 | 2022 | 820 | 0.030 |
Why?
|
Laryngectomy | 2 | 2009 | 245 | 0.030 |
Why?
|
Stroke | 1 | 2017 | 9744 | 0.030 |
Why?
|
DNA, Viral | 1 | 2022 | 2201 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-kit | 2 | 2009 | 723 | 0.030 |
Why?
|
Sulindac | 1 | 2014 | 29 | 0.030 |
Why?
|
Stomatitis | 2 | 2009 | 271 | 0.030 |
Why?
|
Kinetics | 1 | 2022 | 6288 | 0.030 |
Why?
|
Guanine Nucleotide Dissociation Inhibitors | 1 | 1993 | 23 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2022 | 1673 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2019 | 1326 | 0.030 |
Why?
|
Dyspnea | 1 | 2022 | 1352 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2019 | 754 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2019 | 1250 | 0.030 |
Why?
|
Immunity, Cellular | 1 | 2019 | 1560 | 0.030 |
Why?
|
Telomerase | 1 | 2018 | 750 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1086 | 0.030 |
Why?
|
Receptor, erbB-2 | 2 | 2015 | 2598 | 0.030 |
Why?
|
Research Support as Topic | 1 | 2017 | 697 | 0.030 |
Why?
|
Biopsy | 1 | 2024 | 6779 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2014 | 545 | 0.020 |
Why?
|
Carcinoembryonic Antigen | 1 | 2013 | 338 | 0.020 |
Why?
|
Glioblastoma | 1 | 2007 | 3458 | 0.020 |
Why?
|
Mice | 5 | 2019 | 81898 | 0.020 |
Why?
|
Consensus | 1 | 2022 | 3208 | 0.020 |
Why?
|
Mice, Nude | 1 | 2018 | 3618 | 0.020 |
Why?
|
Cancer Vaccines | 1 | 2019 | 1042 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2017 | 3431 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2019 | 3157 | 0.020 |
Why?
|
DNA Mutational Analysis | 2 | 2016 | 4114 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2017 | 2629 | 0.020 |
Why?
|
Palliative Care | 1 | 2005 | 3640 | 0.020 |
Why?
|
Histone Deacetylases | 1 | 2015 | 712 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2021 | 2979 | 0.020 |
Why?
|
Fungal Proteins | 1 | 1994 | 901 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2018 | 2045 | 0.020 |
Why?
|
Ligands | 1 | 2016 | 3274 | 0.020 |
Why?
|
GTP-Binding Proteins | 1 | 1993 | 946 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2018 | 6225 | 0.020 |
Why?
|
Receptors, Somatomedin | 1 | 2008 | 57 | 0.020 |
Why?
|
Receptors, Platelet-Derived Growth Factor | 1 | 2009 | 178 | 0.020 |
Why?
|
Doxorubicin | 1 | 2015 | 2229 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 4570 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2019 | 5502 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1394 | 0.020 |
Why?
|
Gene Amplification | 1 | 2012 | 1088 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2009 | 684 | 0.020 |
Why?
|
Radiotherapy | 1 | 2015 | 1497 | 0.020 |
Why?
|
Organ Specificity | 2 | 2008 | 1968 | 0.020 |
Why?
|
Recurrence | 1 | 2020 | 8507 | 0.020 |
Why?
|
Viral Matrix Proteins | 1 | 2009 | 193 | 0.020 |
Why?
|
Lymphocytes | 1 | 2015 | 2606 | 0.020 |
Why?
|
Cancer Care Facilities | 1 | 2010 | 428 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2023 | 6548 | 0.020 |
Why?
|
Vaccination | 1 | 2019 | 3435 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2008 | 877 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2017 | 5890 | 0.020 |
Why?
|
Neovascularization, Pathologic | 1 | 2016 | 2631 | 0.020 |
Why?
|
Health | 1 | 2009 | 396 | 0.020 |
Why?
|
Genomics | 1 | 2021 | 5922 | 0.020 |
Why?
|
Substrate Specificity | 1 | 2009 | 1750 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2017 | 4410 | 0.010 |
Why?
|
Age Factors | 1 | 2021 | 18397 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5367 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15425 | 0.010 |
Why?
|
DNA Repair | 1 | 1994 | 2050 | 0.010 |
Why?
|
Cloning, Molecular | 3 | 1994 | 4168 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2016 | 4559 | 0.010 |
Why?
|
Regression Analysis | 1 | 2013 | 6329 | 0.010 |
Why?
|
Risk Factors | 3 | 2018 | 74889 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12064 | 0.010 |
Why?
|
MutS Homolog 2 Protein | 2 | 1994 | 200 | 0.010 |
Why?
|
Genetic Testing | 1 | 2017 | 3591 | 0.010 |
Why?
|
Postoperative Care | 1 | 2010 | 1480 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2019 | 18986 | 0.010 |
Why?
|
Pharyngeal Diseases | 1 | 2004 | 134 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2021 | 20146 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2019 | 8623 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2019 | 10451 | 0.010 |
Why?
|
Epitopes | 1 | 2009 | 2526 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2017 | 3235 | 0.010 |
Why?
|
Child | 2 | 2021 | 80670 | 0.010 |
Why?
|
Mitosis | 1 | 2007 | 1176 | 0.010 |
Why?
|
Constriction, Pathologic | 1 | 2004 | 1104 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2024 | 36570 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2019 | 22351 | 0.010 |
Why?
|
DNA-Binding Proteins | 2 | 1994 | 9613 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2014 | 12795 | 0.010 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2008 | 2060 | 0.010 |
Why?
|
Child, Preschool | 1 | 2021 | 42577 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2018 | 18329 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 18076 | 0.010 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2008 | 2887 | 0.010 |
Why?
|
Boston | 1 | 2010 | 9346 | 0.010 |
Why?
|
Drug Delivery Systems | 1 | 2008 | 2210 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2008 | 3440 | 0.010 |
Why?
|
Pedigree | 2 | 1994 | 4539 | 0.010 |
Why?
|
Chromosome Mapping | 2 | 1994 | 4618 | 0.010 |
Why?
|
Transcription Factors | 1 | 2014 | 12159 | 0.010 |
Why?
|
Cytokines | 1 | 2009 | 7438 | 0.010 |
Why?
|
Yolk Sac | 1 | 1993 | 79 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2005 | 3511 | 0.010 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 1994 | 313 | 0.010 |
Why?
|
rac GTP-Binding Proteins | 1 | 1993 | 163 | 0.010 |
Why?
|
cdc42 GTP-Binding Protein | 1 | 1993 | 187 | 0.010 |
Why?
|
Frameshift Mutation | 1 | 1994 | 392 | 0.010 |
Why?
|
Apoptosis | 1 | 2008 | 9514 | 0.010 |
Why?
|
Amino Acid Sequence | 2 | 1994 | 13411 | 0.010 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 1993 | 432 | 0.010 |
Why?
|
Introns | 1 | 1994 | 966 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 1994 | 17609 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2009 | 22248 | 0.010 |
Why?
|
DNA, Complementary | 1 | 1993 | 1989 | 0.010 |
Why?
|
DNA Primers | 1 | 1994 | 2826 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2008 | 15912 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1993 | 2746 | 0.010 |
Why?
|
Sequence Alignment | 1 | 1993 | 2177 | 0.010 |
Why?
|
Genetic Linkage | 1 | 1994 | 2342 | 0.010 |
Why?
|
Exons | 1 | 1994 | 2392 | 0.000 |
Why?
|
DNA, Neoplasm | 1 | 1994 | 1741 | 0.000 |
Why?
|
Diet | 1 | 2006 | 8088 | 0.000 |
Why?
|
Biological Evolution | 1 | 1994 | 1075 | 0.000 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1993 | 1561 | 0.000 |
Why?
|
Base Sequence | 1 | 1994 | 12415 | 0.000 |
Why?
|
DNA | 1 | 1994 | 7210 | 0.000 |
Why?
|